Skip to main content

Table 2 Evolution of anemia and iron biomarker levels by treatment

From: Effect of roxadustat on iron metabolism in patients with peritoneal dialysis: a real-world 24-week study

 

Roxadustat(n = 70)

ESA(n = 36)

Baseline (n = 106)

Week 8 (n = 88)

Week 24 (n = 70)

Baseline (n = 53)

Week 8 (n = 44)

Week 24 (n = 36)

SI, µmol/L

13.54 ± 6.46

14.54 ± 7.41b

14.01 ± 7.12b

12.80 ± 5.39

11.73 ± 5.68b

10.69 ± 7.75b

LogsFt, μg/mL

2.21 ± 0.45

2.03 ± 0.41a

2.10 ± 0.40a

2.24 ± 0.46

2.18 ± 0.38

2.05 ± 0.43a

sFt < 100 ng/mL, n (%)

32 (30.19)

40 (45.45)a

30 (42.86)

16 (30.19)

14 (31.81)

15 (41.67)

TSAT, (%)

32.13 ± 15.23

30.42 ± 14.17

28.87 ± 15.88

31.98 ± 14.85

27.89 ± 13.50

24.13 ± 16.72a

 < 20%, n (%)

24 (22.64)

22 (25.00)

24 (34.29)b

11 (20.75)

13 (29.55)

20 (55.56)c

TIBC, µmol/L

43.33 ± 11.44

47.92 ± 9.40c

50.46 ± 9.63c

42.44 ± 12.03

42.18 ± 7.28b

45.25 ± 9.93b

Hemoglobin, g/L

87.84 ± 9.42

105.77 ± 13.13c

111.73 ± 17.87c

86.66 ± 10.72

99.99 ± 17.85c

106.39 ± 20.67c

LogEPO, mIU/mLd

0.77 ± 0.30

0.83 ± 0.42b

0.90 ± 0.42c

0.78 ± 0.31

1.52 ± 0.48c

1.56 ± 0.62c

  1. Measurement data with a normal distribution are expressed as means ± standard deviation, and nonnormally distributed data are expressed as medians and interquartile range. SI denotes serum iron, sFt denotes serum ferritin, TSAT denotes transferrin saturation, TIBC denotes total iron-binding capacity
  2. aSignificant difference from baseline (P < 0.05)
  3. bSignificant difference between the groups (P < 0.05)
  4. cSignificant differences from baseline (P < 0.05) and between the groups (P < 0.05)
  5. dThe erythropoietin levels mentioned were measured before each administration